<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03328234</url>
  </required_header>
  <id_info>
    <org_study_id>3JECROG-P03</org_study_id>
    <nct_id>NCT03328234</nct_id>
  </id_info>
  <brief_title>Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG-P03</brief_title>
  <official_title>A Randomized Phase III Study of Simultaneous Integrated Boost Intensity Modulated Radiation Therapy (SIB-IMRT) With or Without Concurrent Chemotherapy Followed by Consolidation Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG-P03</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to compare elective nodal irradiation versus involved field
      irradiation with or without concurrent chemotherapy and the addition of consolidation
      chemotherapy for patients with extensive lymphatic metastasis of esophageal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence-free rate（LRFS）</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence-free rate（LRFS）</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence-free rate（LRFS）</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion Rate</measure>
    <time_frame>up to 2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2</enrollment>
  <condition>IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>SIB-IMRT with combined chemotherapy ENI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SIB-IMRT with ENI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SIB-IMRT combined chemotherapy with IFI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SIB-IMRT with IFI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SIB-IMRT</intervention_name>
    <description>Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.</description>
    <arm_group_label>SIB-IMRT with combined chemotherapy ENI</arm_group_label>
    <arm_group_label>SIB-IMRT with ENI</arm_group_label>
    <arm_group_label>SIB-IMRT combined chemotherapy with IFI</arm_group_label>
    <arm_group_label>SIB-IMRT with IFI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>45-50mg/m2, once a week, concurrent with radiotherapy for 5-6weeks</description>
    <arm_group_label>SIB-IMRT with combined chemotherapy ENI</arm_group_label>
    <arm_group_label>SIB-IMRT combined chemotherapy with IFI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platinum-Based Drug</intervention_name>
    <description>Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks</description>
    <arm_group_label>SIB-IMRT with combined chemotherapy ENI</arm_group_label>
    <arm_group_label>SIB-IMRT combined chemotherapy with IFI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>135-150mg/m2 on day1,every 3 weeks, 2 cycles, 1 month after completion of radiotherapy</description>
    <arm_group_label>SIB-IMRT with combined chemotherapy ENI</arm_group_label>
    <arm_group_label>SIB-IMRT with ENI</arm_group_label>
    <arm_group_label>SIB-IMRT combined chemotherapy with IFI</arm_group_label>
    <arm_group_label>SIB-IMRT with IFI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platinum-Based Drug</intervention_name>
    <description>Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin,50mg on day1 ),every 3 weeks, 2 cycles, 1 month after completion of radiotherapy</description>
    <arm_group_label>SIB-IMRT with combined chemotherapy ENI</arm_group_label>
    <arm_group_label>SIB-IMRT with ENI</arm_group_label>
    <arm_group_label>SIB-IMRT combined chemotherapy with IFI</arm_group_label>
    <arm_group_label>SIB-IMRT with IFI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Elective Nodal Irradiation (ENI)</intervention_name>
    <description>CTV was defined as GTV with a 3.0-5.0 cm craniocaudal margin and a 0.6-0.8 cm lateral margin and lymph node regions at high risk.</description>
    <arm_group_label>SIB-IMRT with combined chemotherapy ENI</arm_group_label>
    <arm_group_label>SIB-IMRT with ENI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Involved Field Irradiation (IFI)</intervention_name>
    <description>CTV was defined as GTV with a 3.0-5.0 cm craniocaudal margin and a 0.6-0.8 cm lateral margin and GTVnd with a 0.5-1.0 cm margin.</description>
    <arm_group_label>SIB-IMRT combined chemotherapy with IFI</arm_group_label>
    <arm_group_label>SIB-IMRT with IFI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&lt;70

          -  Diagnosis of clinical stage T2-4N0-1M1（According to UICC 2002）

          -  A untreated squamous esophageal carcinoma

          -  Karnofsky performance status(KPS)≥ 70 and Charlson score ≤3

          -  Adequate organ function

          -  No known history of drug allergy

          -  Blood routine examination : WBC≥4.0

          -  hepatic and renal function are normal

        Exclusion Criteria:

          -  Age≥ 70 or ≤ 16

          -  Already received the treatment of chemotherapy or radiotherapy

          -  Pregnant or lactating females

          -  Known drug allergy

          -  Without agreement of informed consent form

          -  Insufficient hepatorenal function or Blood routine examination

          -  Severe cardiovascular diseases, diabetes with uncontrolled blood sugar, mental
             disorders, uncontrolled severe infection, active ulceration which need intervention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xin Wang, MD</last_name>
    <phone>+86-13311583220</phone>
    <email>beryl_wx2000@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Wang, MD</last_name>
      <phone>+861013311583220</phone>
      <email>beryl_wx2000@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2017</study_first_submitted>
  <study_first_submitted_qc>October 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2017</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zefen Xiao</investigator_full_name>
    <investigator_title>Pricipal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

